Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach.

ABSTRACT: In September 2019, the U.S. Food and Drug Administration approved oral semaglutide as the first orally administered glucagon-like peptide 1 (GLP-1) receptor agonist for treating people with type 2 diabetes. Although injectable GLP-1 receptor agonists are well-established treatment options for people with type 2 diabetes, clinical experience with an oral formulation in this class is limited. This article provides practical guidance for diabetes care and education specialists on how to effectively counsel patients initiating therapy with oral semaglutide on appropriate administration of the treatment and its possible effects on glycemic control, body weight, and quality of life. Strategies for mitigating potential side effects typical of the GLP-1 receptor agonist class, namely nausea, vomit

SUBMITTER: Isaacs DM 

PROVIDER: S-EPMC7887531 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature